NCT06592417View on ClinicalTrials.gov

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

May 17, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Malignant Solid Tumor
Interventions
DRUG

JSKN016 injection

JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.

Trial Locations (2)

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

510080

RECRUITING

Sun Yat-sen Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY